{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T23:44:27Z","timestamp":1786146267727,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009164","name":"H Lee Moffitt Cancer Center and Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009164","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008900","name":"University of South Florida","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008900","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clbc.2026.06.003","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:29:15Z","timestamp":1781627355000},"page":"7-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Cohort Study of the Effectiveness of Trastuzumab Deruxtecan for Treating Metastatic Progressive HER2-Positive Breast Cancer"],"prefix":"10.1016","volume":"26","author":[{"given":"Ameer","family":"Basta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Lien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabris","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junmin","family":"Whiting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Armitage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aixa E.","family":"Soyano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avan","family":"Armaghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta","family":"Loftus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Dvir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo S.","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatem","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Czerniecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3303-3234","authenticated-orcid":false,"given":"Ricardo L.B.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.clbc.2026.06.003_bib0001","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1200\/JCO.2009.25.6529","article-title":"American Society of Clinical Oncology\/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer","volume":"28","author":"Hammond","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clbc.2026.06.003_bib0002","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"Howlader","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.clbc.2026.06.003_bib0003","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5858\/arpa.2022-0384-CP","article-title":"Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression rates in invasive breast carcinoma: a study of 21 institutions","volume":"149","author":"Mais","year":"2025","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"10.1016\/j.clbc.2026.06.003_bib0004","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11050646","article-title":"Gene expression and miRNAs profiling: function and regulation in Human epidermal growth factor receptor 2 (HER2)-positive breast cancer","volume":"11","author":"Sareyeldin","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.clbc.2026.06.003_bib0005","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clbc.2026.06.003_bib0006","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clbc.2026.06.003_bib0007","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13058-020-1252-7","article-title":"HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates","volume":"22","author":"Ocana","year":"2020","journal-title":"Breast Cancer Res"},{"issue":"1","key":"10.1016\/j.clbc.2026.06.003_bib0008","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12943-023-01716-y","article-title":"CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer","volume":"22","author":"Xing","year":"2023","journal-title":"Mol Cancer"},{"key":"10.1016\/j.clbc.2026.06.003_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.100947","article-title":"PDPN positive CAFs contribute to HER2 positive breast cancer resistance to trastuzumab by inhibiting antibody-dependent NK cell-mediated cytotoxicity","volume":"68","author":"Du","year":"2023","journal-title":"Drug Resist Updat"},{"issue":"4","key":"10.1016\/j.clbc.2026.06.003_bib0010","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1002\/jcp.29216","article-title":"Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy","volume":"235","author":"Derakhshani","year":"2020","journal-title":"J Cell Physiol"},{"issue":"6","key":"10.1016\/j.clbc.2026.06.003_bib0011","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S1470-2045(17)30312-1","article-title":"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial","volume":"18","author":"Dieras","year":"2017","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.clbc.2026.06.003_bib0012","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1470-2045(17)30313-3","article-title":"Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial","volume":"18","author":"Krop","year":"2017","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.clbc.2026.06.003_bib0013","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab Deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"issue":"10371","key":"10.1016\/j.clbc.2026.06.003_bib0014","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.clbc.2026.06.003_bib0015","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab Deruxtecan versus Trastuzumab Emtansine for breast cancer","volume":"386","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clbc.2026.06.003_bib0016","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial","volume":"30","author":"Cortes","year":"2024","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.clbc.2026.06.003_bib0017","doi-asserted-by":"crossref","first-page":"171","DOI":"10.4103\/picr.picr_62_21","article-title":"Introduction to real-world evidence studies","volume":"12","author":"Chodankar","year":"2021","journal-title":"Perspect Clin Res"},{"key":"10.1016\/j.clbc.2026.06.003_bib0018","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.clbc.2026.06.003_bib0019","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: american Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10390","key":"10.1016\/j.clbc.2026.06.003_bib0020","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial","volume":"401","author":"Andre","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2026.06.003_bib0021","doi-asserted-by":"crossref","DOI":"10.5772\/intechopen.1005693","article-title":"Prognostic index for predicting outcomes of Trastuzumab Deruxtecan in HER2 expressing metastatic breast cancer: a real-world multicenter study","author":"Xue","year":"2025","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.clbc.2026.06.003_bib0022","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S1470-2045(17)30604-6","article-title":"Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study","volume":"18","author":"Doi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.clbc.2026.06.003_bib0023","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/cpt.2291","article-title":"Exposure-response relationships in patients with HER2-positive metastatic breast cancer and other solid tumors treated with Trastuzumab Deruxtecan","volume":"110","author":"Yin","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.clbc.2026.06.003_bib0024","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/COC.0000000000001126","article-title":"Safety and efficacy of Trastuzumab Deruxtecan for metastatic HER2+ and HER2-low breast cancer: an updated systematic review and meta-analysis of clinical trials","volume":"47","author":"Qureshi","year":"2024","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clbc.2026.06.003_bib0025","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/oncolo\/oyad308","article-title":"Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: the DE-REAL study","volume":"29","author":"Botticelli","year":"2024","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.clbc.2026.06.003_bib0026","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.3390\/cancers13122927","article-title":"Brain metastases in HER2-positive breast cancer: current and novel treatment strategies","volume":"13","author":"Garcia-Alvarez","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.clbc.2026.06.003_bib0027","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/neuonc\/noac144","article-title":"Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: the DEBBRAH trial","volume":"25","author":"Perez-Garcia","year":"2023","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.clbc.2026.06.003_bib0028","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","article-title":"Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial","volume":"30","author":"Harbeck","year":"2024","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.clbc.2026.06.003_bib0029","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/neuonc\/noac195","article-title":"A phase I\/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: safety, efficacy, and cerebrospinal fluid pharmacokinetics","volume":"25","author":"Kumthekar","year":"2023","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.clbc.2026.06.003_bib0030","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s10549-019-05170-7","article-title":"Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy","volume":"175","author":"Figura","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"21","key":"10.1016\/j.clbc.2026.06.003_bib0031","doi-asserted-by":"crossref","first-page":"7935","DOI":"10.1002\/cam4.3422","article-title":"Intra-CSF topotecan in treatment of breast cancer patients with leptomeningeal metastases","volume":"9","author":"Jaeckle","year":"2020","journal-title":"Cancer Med"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152682092600087X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152682092600087X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T23:30:32Z","timestamp":1786145432000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152682092600087X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S152682092600087X"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2026.06.003","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Cohort Study of the Effectiveness of Trastuzumab Deruxtecan for Treating Metastatic Progressive HER2-Positive Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2026.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}